The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury.
Adipose Tissue
/ metabolism
Administration, Oral
Akkermansia
/ cytology
Animals
Anti-Inflammatory Agents
/ administration & dosage
Carbon Tetrachloride
/ adverse effects
Cell Line
Cytokines
/ genetics
Diet, High-Fat
/ adverse effects
Disease Models, Animal
Extracellular Vesicles
Gastrointestinal Microbiome
Gene Expression
Hepatic Stellate Cells
/ drug effects
Humans
Liver
/ metabolism
Liver Cirrhosis
/ chemically induced
Male
Mice
Mice, Inbred C57BL
Probiotics
/ administration & dosage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 02 2022
14 02 2022
Historique:
received:
27
07
2021
accepted:
24
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Inflammation plays a critical role in the promotion of hepatocyte damage and liver fibrosis. In recent years the protective role of Akkermansia muciniphila, a next-generation beneficial microbe, has been suggested for metabolic and inflammatory disorders. In this study, we aimed to evaluate the effects of live and pasteurized A. muciniphila and its extra cellular vesicles (EVs) on inflammatory markers involved in liver fibrosis in a mouse model of a high-fat diet (HFD)/carbon tetrachloride (CCl
Identifiants
pubmed: 35165344
doi: 10.1038/s41598-022-06414-1
pii: 10.1038/s41598-022-06414-1
pmc: PMC8844054
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2453Informations de copyright
© 2022. The Author(s).
Références
Seto, W.-K. & Mandell, M. S. Chronic liver disease: Global perspectives and future challenges to delivering quality health care. Plos one 16, e0243607 (2021).
Cotter, T. G. & Rinella, M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158, 1851–1864 (2020).
pubmed: 32061595
doi: 10.1053/j.gastro.2020.01.052
Wang, S., Toy, M., Hang Pham, T. T. & So, S. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the US, 2010–2019. PloS one 15, e0239393 (2020).
Khomich, O., Ivanov, A. V. & Bartosch, B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. Cells 9, 24 (2020).
doi: 10.3390/cells9010024
Kong, M. et al. Ablation of serum response factor in hepatic stellate cells attenuates liver fibrosis. J. Mol. Med. 97, 1521–1533 (2019).
pubmed: 31435710
doi: 10.1007/s00109-019-01831-8
Thursby, E. & Juge, N. Introduction to the human gut microbiota. Biochem. J. 474, 1823–1836 (2017).
pubmed: 28512250
doi: 10.1042/BCJ20160510
Jiang, L. & Schnabl, B. Gut microbiota in liver disease: What do we know and what do we not know?. Physiology 35, 261–274 (2020).
pubmed: 32490750
pmcid: 7474259
doi: 10.1152/physiol.00005.2020
Acharya, C. & Bajaj, J. S. Chronic liver diseases and the microbiome—translating our knowledge of gut microbiota to management of chronic liver disease. Gastroenterology 160, 556–572 (2021).
pubmed: 33253686
doi: 10.1053/j.gastro.2020.10.056
Wu, W. et al. Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front. Microbiol. 8, 1804 (2017).
pubmed: 29033903
pmcid: 5626943
doi: 10.3389/fmicb.2017.01804
Derrien, M., Vaughan, E. E., Plugge, C. M. & de Vos, W. M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 54, 1469–1476 (2004).
Reunanen, J. et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl. Environ. Microbiol. 81, 3655–3662 (2015).
pubmed: 25795669
pmcid: 4421065
doi: 10.1128/AEM.04050-14
Zhang, T., Li, Q., Cheng, L., Buch, H. & Zhang, F. Akkermansia muciniphila is a promising probiotic. Microb. Biotechnol. 12, 1109–1125 (2019).
pubmed: 31006995
pmcid: 6801136
doi: 10.1111/1751-7915.13410
Chelakkot, C. et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp. Mol. Med. 50, e450–e450 (2018).
pubmed: 29472701
pmcid: 5903829
doi: 10.1038/emm.2017.282
Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).
pubmed: 27892954
doi: 10.1038/nm.4236
Dehghanbanadaki, H. et al. Global scientific output trend for Akkermansia muciniphila research: a bibliometric and scientometric analysis. BMC Med. Inform. Decis. Mak. 20, 1–12 (2020).
doi: 10.1186/s12911-020-01312-w
Roshanravan, N. et al. A comprehensive systematic review of the effectiveness of Akkermansia muciniphila, a member of the gut microbiome, for the management of obesity and associated metabolic disorders. Arch. Physiol. Biochem., 1–11 (2021).
Ashrafian, F. et al. Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice. Microb. Cell Fact. 20, 1–17 (2021).
doi: 10.1186/s12934-021-01709-w
Brown, L., Wolf, J. M., Prados-Rosales, R. & Casadevall, A. Through the wall: Extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat. Rev. Microbiol. 13, 620–630 (2015).
pubmed: 26324094
pmcid: 4860279
doi: 10.1038/nrmicro3480
Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383 (2013).
pubmed: 23420871
pmcid: 3575529
doi: 10.1083/jcb.201211138
Yáñez-Mó, M. et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesic. 4, 27066 (2015).
doi: 10.3402/jev.v4.27066
Schwechheimer, C. & Kuehn, M. J. Outer-membrane vesicles from Gram-negative bacteria: Biogenesis and functions. Nat. Rev. Microbiol. 13, 605–619 (2015).
pubmed: 26373371
pmcid: 5308417
doi: 10.1038/nrmicro3525
Stentz, R., Carvalho, A. L., Jones, E. J. & Carding, S. R. Fantastic voyage: The journey of intestinal microbiota-derived microvesicles through the body. Biochem. Soc. Trans. 46, 1021–1027 (2018).
pubmed: 30154095
pmcid: 6195637
doi: 10.1042/BST20180114
Jafari, B., Nejad, R. A. K., Vaziri, F. & Siadat, S. D. Evaluation of the effects of extracellular vesicles derived from Faecalibacterium prausnitzii on lung cancer cell line. Biologia 74, 889–898 (2019).
doi: 10.2478/s11756-019-00229-8
Rabiei, N. et al. Induction effects of Faecalibacterium prausnitzii and its extracellular vesicles on toll-like receptor signaling pathway gene expression and cytokine level in human intestinal epithelial cells. Cytokine 121, 154718 (2019).
Raftar, S. K. A. et al. The Anti-fibrotic Effects of Heat-Killed Akkermansia muciniphila MucT on Liver Fibrosis Markers and Activation of Hepatic Stellate Cells. Probiot. Antimicrob. Prot., 1–12 (2021).
Kang, C.-s. et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PloS one 8, e76520 (2013).
Kubota, N. et al. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Clin. Exp. Pharmacol. Physiol. 40, 422–430 (2013).
pubmed: 23611112
doi: 10.1111/1440-1681.12102
Kim, J. E. et al. Molecular characterization of constipation disease as novel phenotypes in CRISPR-Cas9-generated leptin knockout mice with obesity. Int. J. Mol. Sci. 21, 9464 (2020).
pmcid: 7763920
doi: 10.3390/ijms21249464
Shelby, R. D. et al. Development of a standardized scoring system to assess a murine model of Clostridium difficile colitis. J. Invest. Surg. 33, 887–895 (2020).
pubmed: 30892111
doi: 10.1080/08941939.2019.1571129
Chen, X. et al. A mouse model of Clostridium difficile–associated disease. Gastroenterology 135, 1984–1992 (2008).
pubmed: 18848941
doi: 10.1053/j.gastro.2008.09.002
Anzai, Á. et al. Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats. Sci. Rep. 7, 1–12 (2017).
doi: 10.1038/s41598-017-13451-8
Kleiner, D. E. Histopathological challenges in suspected drug-induced liver injury. Liver Int. 38, 198–209 (2018).
pubmed: 28865179
doi: 10.1111/liv.13584
Goodman, Z. D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol. 47, 598–607 (2007).
pubmed: 17692984
doi: 10.1016/j.jhep.2007.07.006
Del Campo, J. A., Gallego, P. & Grande, L. Role of inflammatory response in liver diseases: Therapeutic strategies. World J. Hepatol. 10, 1 (2018).
pubmed: 29399273
pmcid: 5787673
doi: 10.4254/wjh.v10.i1.1
Duarte, S. M., Stefano, J. T. & Oliveira, C. P. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann. Hepatol. 18, 416–421 (2019).
pubmed: 31036494
doi: 10.1016/j.aohep.2019.04.006
Ilan, Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J. Gastroenterol.: WJG 18, 2609 (2012).
pubmed: 22690069
pmcid: 3369997
doi: 10.3748/wjg.v18.i21.2609
Ashrafian, F. et al. Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front. Microbiol. 10, 2155 (2019).
pubmed: 31632356
pmcid: 6779730
doi: 10.3389/fmicb.2019.02155
Grander, C. et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67, 891–901 (2018).
doi: 10.1136/gutjnl-2016-313432
Nishizawa, H. et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci. Rep. 6, 1–11 (2016).
doi: 10.1038/srep34605
Hribal, M. L. et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 98, E304–E308 (2013).
pubmed: 23316084
doi: 10.1210/jc.2012-3290
Wheatcroft, S. B. & Kearney, M. T. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and-2: Implications for metabolic homeostasis. Trends Endocrinol. Metab. 20, 153–162 (2009).
pubmed: 19349193
doi: 10.1016/j.tem.2009.01.002
Kasprzak, A., Kwasniewski, W., Adamek, A. & Gozdzicka-Jozefiak, A. Insulin-like growth factor (IGF) axis in cancerogenesis. Mut. Res./Rev. Mut. Res. 772, 78–104 (2017).
doi: 10.1016/j.mrrev.2016.08.007
Takahashi, Y. The role of growth hormone and insulin-like growth factor-I in the liver. Int. J. Mol. Sci. 18, 1447 (2017).
pmcid: 5535938
doi: 10.3390/ijms18071447
Krenkel, O. & Tacke, F. Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17, 306–321 (2017).
pubmed: 28317925
doi: 10.1038/nri.2017.11
Cai, J., Zhang, X.-J. & Li, H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 29, 712–722 (2018).
pubmed: 30131212
doi: 10.1016/j.tem.2018.08.003
Nagai, Y., Watanabe, Y. & Takatsu, K. The TLR family protein RP105/MD-1 complex: A new player in obesity and adipose tissue inflammation. Adipocyte 2, 61–66 (2013).
pubmed: 23805400
pmcid: 3661108
doi: 10.4161/adip.22929
Yan, H. et al. TLR5 activation in hepatocytes alleviates the functional suppression of intrahepatic CD8+ T cells. Immunology 161, 325–344 (2020).
pubmed: 32852795
pmcid: 7692256
doi: 10.1111/imm.13251
Brackett, C. M. et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc. Natl. Acad. Sci. 113, E874–E883 (2016).
pubmed: 26831100
pmcid: 4763744
doi: 10.1073/pnas.1521359113
Roh, Y. S., Zhang, B., Loomba, R. & Seki, E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am. J. Physiol.-Gastrointest. Liver Physiol. 309, G30-G41 (2015).
Bukong, T. N. et al. Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use. J. Hepatol. 69, 1145–1154 (2018).
pubmed: 30030149
pmcid: 6310218
doi: 10.1016/j.jhep.2018.07.005
Keshavarz Azizi Raftar, S. et al. The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury. Microbiology Spectrum 9, e00484–00421 (2021).
Ashrafian, F. et al. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice. Sci. Rep. 11, 1–13 (2021).
doi: 10.1038/s41598-021-95738-5
Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 139, 323–334. e327 (2010).
Zhou, Z. et al. Toll-Like Receptor 5 Signaling Ameliorates Liver Fibrosis by Inducing Interferon β–Modulated IL-1 Receptor Antagonist in Mice. Am. J. Pathol. 190, 614–629 (2020).
pubmed: 31972159
doi: 10.1016/j.ajpath.2019.11.012
Shu, M., Huang, D.-D., Hung, Z.-A., Hu, X.-R. & Zhang, S. Inhibition of MAPK and NF-κB signaling pathways alleviate carbon tetrachloride (CCl4)-induced liver fibrosis in Toll-like receptor 5 (TLR5) deficiency mice. Biochem. Biophys. Res. Commun. 471, 233–239 (2016).
pubmed: 26845355
doi: 10.1016/j.bbrc.2016.01.119
Kesar, V. & Odin, J. A. Toll-like receptors and liver disease. Liver Int. 34, 184–196 (2014).
pubmed: 24118797
doi: 10.1111/liv.12315
Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: From physiopathology to therapy. J. Hepatol. 64, 1403–1415 (2016).
pubmed: 26867490
doi: 10.1016/j.jhep.2016.02.004
Widjaja, A. A., Chothani, S. P. & Cook, S. A. Different roles of interleukin 6 and interleukin 11 in the liver: Implications for therapy. Hum. Vaccin. Immunother. 16, 2357–2362 (2020).
pubmed: 32530750
pmcid: 7644218
doi: 10.1080/21645515.2020.1761203
Ayelign, B. et al. Association of IL-10 (− 1082 A/G) and IL-6 (− 174 G/C) gene polymorphism with type 2 diabetes mellitus in Ethiopia population. BMC Endocr. Disord. 21, 1–8 (2021).
doi: 10.1186/s12902-021-00738-1
Wan, X. et al. PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response. FASEB J. 34, 10751–10761 (2020).
pubmed: 32633848
doi: 10.1096/fj.201902476R
Tilg, H. & Moschen, A. R. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J. Hepatol. 55, 960–962 (2011).
pubmed: 21742000
doi: 10.1016/j.jhep.2011.04.007
Niederreiter, L. & Tilg, H. Cytokines and fatty liver diseases. Liver Research 2, 14–20 (2018).
doi: 10.1016/j.livres.2018.03.003
Jantararussamee, C., Rodniem, S., Taweechotipatr, M., Showpittapornchai, U. & Pradidarcheep, W. Hepatoprotective effect of probiotic lactic acid bacteria on thioacetamide-induced liver fibrosis in rats. Probiot. Antimicrob. Prot. 13, 40–50 (2021).
doi: 10.1007/s12602-020-09663-6
Huck, O. et al. Akkermansia muciniphila reduces Porphyromonas gingivalis-induced inflammation and periodontal bone destruction. J. Clin. Periodontol. 47, 202–212 (2020).
pubmed: 31674689
doi: 10.1111/jcpe.13214
Moschen, A. R. et al. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol. Med. 17, 840–845 (2011).
pubmed: 21394384
pmcid: 3146615
doi: 10.2119/molmed.2010.00108
Nov, O. et al. Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PloS one 8, e53626 (2013).
Tanaka, N., Aoyama, T., Kimura, S. & Gonzalez, F. J. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol. Ther. 179, 142–157 (2017).
pubmed: 28546081
pmcid: 6659998
doi: 10.1016/j.pharmthera.2017.05.011
Rudraiah, S., Zhang, X. & Wang, L. Nuclear receptors as therapeutic targets in liver disease: are we there yet?. Annu. Rev. Pharmacol. Toxicol. 56, 605–626 (2016).
pubmed: 26738480
pmcid: 4919666
doi: 10.1146/annurev-pharmtox-010715-103209
Wu, L. et al. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed. Pharmacother. 136, 111255 (2021).
Choi, J. H. et al. Platyconic acid A, platycodi radix-derived saponin, suppresses TGF-β1-induced activation of hepatic stellate cells via blocking SMAD and activating the PPARγ signaling pathway. Cells 8, 1544 (2019).
pmcid: 6952772
doi: 10.3390/cells8121544
Nakamura, F. et al. Fragmented lactic Acid bacterial cells activate peroxisome proliferator-activated receptors and ameliorate Dyslipidemia in obese mice. J. Agric. Food Chem. 64, 2549–2559 (2016).
pubmed: 26927959
doi: 10.1021/acs.jafc.5b05827
Yang, X., Gonzalez, F. J., Huang, M. & Bi, H. Nuclear receptors and non-alcoholic fatty liver disease: An update. Liver Research 4, 88–93 (2020).
doi: 10.1016/j.livres.2020.03.001